Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.

  • 1.

    Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1:2335.

  • 2.

    Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1):115.

  • 3.

    Fortner BV, Schwartzberg L, Tauer K. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005;13:522528.

    • Search Google Scholar
    • Export Citation
  • 4.

    Dale DC, McCarter GC, Crawford J, Lyman GH. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw 2003;1:440454.

    • Search Google Scholar
    • Export Citation
  • 5.

    US Food and Drug Administration. FDA Medical Imaging Drugs Advisory Committee and the Oncologic Drugs Advisory Committee Advisory Committee Briefing Materials: Available for public release. Tbo-filgrastim. 2013. Accessed July 28, 2016.

    • Search Google Scholar
    • Export Citation
  • 6.

    Hirsch BR, Lyman GH. Will biosimilars gain momentum? J Natl Compr Canc Netw 2013;11:12911297.

  • 7.

    Food and Drug Administration. Tbo-filgrastim [prescribing information]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125294s0000lbl.pdf. Accessed July 28, 2016.

    • Search Google Scholar
    • Export Citation
  • 8.

    Farese AM, Cohen MV, Katz BP. Filgrastim improves survival in lethally irradiated nonhuman primates. Radiat Res 2013;179:89100.

  • 9.

    Sourgens H, Lefrere F. A systematic review of available clinical evidence—filgrastim compared with lenograstim. Int J Clin Pharmacol Ther 2011;49:510518.

    • Search Google Scholar
    • Export Citation
  • 10.

    Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor. Clin Ther 1993;15:1929; discussion 18.

    • Search Google Scholar
    • Export Citation
  • 11.

    Moore DC. Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia. P T 2016;41:765768.

  • 12.

    Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427437.

  • 13.

    Aslani A, Smith RC, Allen BJ. The predictive value of body protein for chemotherapy-induced toxicity. Cancer 2000;88:796803.

  • 14.

    Chrischilles E, Delgado DJ, Stolshek BS. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002;9:203211.

    • Search Google Scholar
    • Export Citation
  • 15.

    Lyman GH, Dale DC, Friedberg J. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:43024311.

    • Search Google Scholar
    • Export Citation
  • 16.

    Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003;98:24022409.

    • Search Google Scholar
    • Export Citation
  • 17.

    Lyman GH, Morrison VA, Dale DC. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:20692076.

    • Search Google Scholar
    • Export Citation
  • 18.

    Morrison VA, Picozzi V, Scott S. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:4756.

    • Search Google Scholar
    • Export Citation
  • 19.

    Lyman GH, Kuderer NM, Crawford J. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:19171927.

    • Search Google Scholar
    • Export Citation
  • 20.

    Smith TJ, Bohlke K, Lyman GH. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2015;33:31993212.

    • Search Google Scholar
    • Export Citation
  • 21.

    Aapro MS, Bohlius J, Cameron DA. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:832.

    • Search Google Scholar
    • Export Citation
  • 22.

    Vogel CL, Wojtukiewicz MZ, Carroll RR. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23:1178-1184.

    • Search Google Scholar
    • Export Citation
  • 23.

    Timmer-Bonte JN, de Boo TM, Smit HJ. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. J Clin Oncol 2005;23:79747984.

    • Search Google Scholar
    • Export Citation
  • 24.

    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004;100:228237.

    • Search Google Scholar
    • Export Citation
  • 25.

    Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol 2004;50:129146.

    • Search Google Scholar
    • Export Citation
  • 26.

    Lyman GH. Risk assessment in oncology clinical practice. From risk factors to risk models. Oncology (Williston Park) 2003;17:813.

  • 27.

    Weycker D, Li X, Tzivelekis S. Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 2017;25:439447.

    • Search Google Scholar
    • Export Citation
  • 28.

    Neupogen (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2016.

  • 29.

    Meropol NJ, Miller LL, Korn EL. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:12011203.

    • Search Google Scholar
    • Export Citation
  • 30.

    Rowinsky EK, Grochow LB, Sartorius SE. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996;14:12241235.

    • Search Google Scholar
    • Export Citation
  • 31.

    Kaufman PA, Paroly W, Rinaldi D. Randomized double blind phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with docetaxel, doxorubicin and cyclophosphamide (TAC) in women with early stage and advanced breast cancer. Breast Cancer Res Treat 2004;88:S59.

    • Search Google Scholar
    • Export Citation
  • 32.

    Saven A, Schwartzberg L, Kaywin P. Randomized, double-blind, phase 2, study evaluating same-day vs next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin's lymphoma patients [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7570.

    • Search Google Scholar
    • Export Citation
  • 33.

    Vance KT, Carpenter J. Same day administration of pegfilgrastim with dose dense doxorubicin in early breast cancer patients [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 671.

    • Search Google Scholar
    • Export Citation
  • 34.

    Hoffmann PS. Administration of pegfilgrastim on the same day or next day of chemotherapy [abstract]. J Clin Oncol 2005;23(Suppl 16):Abstract 8137.

    • Search Google Scholar
    • Export Citation
  • 35.

    Belani CP, Ramalingam S, Al-Janadi A. A randomized double-blind phase II study to evaluate same-day vs next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7110.

    • Search Google Scholar
    • Export Citation
  • 36.

    Lokich J. Same-day pegfilgrastim and chemotherapy. Cancer Invest 2005;23:573576.

  • 37.

    Schuman SI, Lambrou N, Robson K. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 2009;7:225228.

    • Search Google Scholar
    • Export Citation
  • 38.

    Whitworth JM, Matthews KS, Shipman KA. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 2009;112:601604.

    • Search Google Scholar
    • Export Citation
  • 39.

    Neulasta (pegfilgrastim) [prescribing information]. Thousand Oaks, CA: Amgen; 2015.

  • 40.

    American Society of Clinical Oncology. Letter to CMS regarding “Neulasta administered same day as chemotherapy.” 2012. Available at: http://www.wsmos.org/assets/Letter%20to%20CMS%20RAC%20Audit%20on%20Neulasta%20110912%20lthd.pdf. Accessed July 28, 2016.

    • Search Google Scholar
    • Export Citation
  • 41.

    Yang BB, Morrow PK, Wu X. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol 2015;75:11991206.

    • Search Google Scholar
    • Export Citation
  • 42.

    Green MD, Koelbl H, Baselga J. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:2935.

    • Search Google Scholar
    • Export Citation
  • 43.

    Watanabe T, Tobinai K, Shibata T. Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 trial. J Clin Oncol 2011;29:39903998.

    • Search Google Scholar
    • Export Citation
  • 44.

    Hecht JR, Pillai M, Gollard R. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2010;9:95101.

    • Search Google Scholar
    • Export Citation
  • 45.

    Brusamolino E, Rusconi C, Montalbetti L. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91:496502.

    • Search Google Scholar
    • Export Citation
  • 46.

    Burstein HJ, Parker LM, Keshaviah A. Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 2005;23:83408347.

    • Search Google Scholar
    • Export Citation
  • 47.

    Jones RL, Walsh G, Ashley S. A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 2009;100:305310.

    • Search Google Scholar
    • Export Citation
  • 48.

    Pirker R, Ulsperger E, Messner J. Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. Lung 2006;184:279285.

    • Search Google Scholar
    • Export Citation
  • 49.

    Gisselbrecht C, Haioun C, Lepage E. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte. Leuk Lymphoma 1997;25:289300.

    • Search Google Scholar
    • Export Citation
  • 50.

    Trillet-Lenoir V, Green J, Manegold C. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319324.

    • Search Google Scholar
    • Export Citation
  • 51.

    Bui BN, Chevallier B, Chevreau C. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol 1995;13:26292636.

    • Search Google Scholar
    • Export Citation
  • 52.

    Chevallier B, Chollet P, Merrouche Y. Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 1995;13:15641571.

    • Search Google Scholar
    • Export Citation
  • 53.

    Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164170.

    • Search Google Scholar
    • Export Citation
  • 54.

    Gatzemeier U, Kleisbauer JP, Drings P. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study. Am J Clin Oncol 2000;23:393400.

    • Search Google Scholar
    • Export Citation
  • 55.

    Muhonen T, Jantunen I, Pertovaara H. Prophylactic filgrastim (G-CSF) during mitomycin-C, mitoxantrone, and methotrexate (MMM) treatment for metastatic breast cancer. A randomized study. Am J Clin Oncol 1996;19:232234.

    • Search Google Scholar
    • Export Citation
  • 56.

    Osby E, Hagberg H, Kvaloy S. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003;101:38403848.

    • Search Google Scholar
    • Export Citation
  • 57.

    Pettengell R, Gurney H, Radford JA. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:14301436.

    • Search Google Scholar
    • Export Citation
  • 58.

    Zinzani PL, Pavone E, Storti S. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89:39743979.

    • Search Google Scholar
    • Export Citation
  • 59.

    Burdach SE, Muschenich M, Josephs W. Granulocyte-macrophage-colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study. Cancer 1995;76:510516.

    • Search Google Scholar
    • Export Citation
  • 60.

    Eguchi K, Kabe J, Kudo S. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol 1994;34:3743.

    • Search Google Scholar
    • Export Citation
  • 61.

    Jones SE, Schottstaedt MW, Duncan LA. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. J Clin Oncol 1996;14:29762983.

    • Search Google Scholar
    • Export Citation
  • 62.

    Arnberg H, Letocha H, Nou F. GM-CSF in chemotherapy-induced febrile neutropenia—a double-blind randomized study. Anticancer Res 1998;18:12551260.

    • Search Google Scholar
    • Export Citation
  • 63.

    Gerhartz HH, Engelhard M, Meusers P. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993;82:23292339.

    • Search Google Scholar
    • Export Citation
  • 64.

    Rowe JM, Andersen JW, Mazza JJ. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995;86:457462.

    • Search Google Scholar
    • Export Citation
  • 65.

    Doorduijn JK, van der Holt B, van Imhoff GW. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:30413050.

    • Search Google Scholar
    • Export Citation
  • 66.

    Fossa SD, Kaye SB, Mead GM. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716724.

    • Search Google Scholar
    • Export Citation
  • 67.

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 68.

    Pfreundschuh M, Trumper L, Kloess M. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634641.

    • Search Google Scholar
    • Export Citation
  • 69.

    Gutierrez M, Chabner BA, Pearson D. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:36333642.

    • Search Google Scholar
    • Export Citation
  • 70.

    Bohlius J, Herbst C, Reiser M. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008:CD003189.

    • Search Google Scholar
    • Export Citation
  • 71.

    Sung L, Nathan PC, Alibhai SM. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007;147:400411.

    • Search Google Scholar
    • Export Citation
  • 72.

    Clark OA, Lyman GH, Castro AA. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23:41984214.

    • Search Google Scholar
    • Export Citation
  • 73.

    Mhaskar R, Clark OA, Lyman G. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014:CD003039.

    • Search Google Scholar
    • Export Citation
  • 74.

    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:31583167.

    • Search Google Scholar
    • Export Citation
  • 75.

    Lyman GH, Dale DC, Wolff DA. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010;28:29142924.

    • Search Google Scholar
    • Export Citation
  • 76.

    del Giglio A, Eniu A, Ganea-Motan D. XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332.

    • Search Google Scholar
    • Export Citation
  • 77.

    Engert A, Griskevicius L, Zyuzgin Y. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374379.

    • Search Google Scholar
    • Export Citation
  • 78.

    Gatzemeier U, Ciuleanu T, Dediu M. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009;4:736740.

    • Search Google Scholar
    • Export Citation
  • 79.

    Engert A, del Giglio A, Bias P. Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma. Onkologie 2009;32:599604.

    • Search Google Scholar
    • Export Citation
  • 80.

    Lubenau H, Bias P, Maly AK. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 2009;23:4351.

    • Search Google Scholar
    • Export Citation
  • 81.

    Lubenau H, Sveikata A, Gumbrevicius G. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 2009;47:275282.

    • Search Google Scholar
    • Export Citation
  • 82.

    Food and Drug Administration. Filgrastim label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103353s5188.pdf. Accessed August 22, 2017.

    • Search Google Scholar
    • Export Citation
  • 83.

    Food and Drug Administration. Pegfilgrastim label information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125031s184lbl.pdf. Accessed August 22, 2017.

    • Search Google Scholar
    • Export Citation
  • 84.

    Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013;368:11311139.

    • Search Google Scholar
    • Export Citation
  • 85.

    Kirshner JJ, Heckler CE, Janelsins MC. Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 2012;30:19741979.

    • Search Google Scholar
    • Export Citation
  • 86.

    Kubista E, Glaspy J, Holmes FA. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 2003;3:391398.

    • Search Google Scholar
    • Export Citation
  • 87.

    Heil G, Hoelzer D, Sanz MA. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997;90:47104718.

    • Search Google Scholar
    • Export Citation
  • 88.

    Kroschinsky F, Holig K, Ehninger G. The role of pegfilgrastim in mobilization of hematopoietic stem cells. Transfus Apher Sci 2008;38:237244.

    • Search Google Scholar
    • Export Citation
  • 89.

    Kuderer NM, Dale DC, Crawford J. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:22582266.

    • Search Google Scholar
    • Export Citation
  • 90.

    Tigue CC, McKoy JM, Evens AM. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 2007;40:185192.

    • Search Google Scholar
    • Export Citation
  • 91.

    Akyol G, Pala C, Yildirim A. A rare but severe complication of filgrastim in a healthy donor: splenic rupture. Transfus Apher Sci 2014;50:5355.

    • Search Google Scholar
    • Export Citation
  • 92.

    Funes C, Garcia-Candel F, Majado MJ. Splenic rupture in a plasma cell leukemia, mobilized with G-CSF for autologous stem cell transplant. J Clin Apher 2010;25:223225.

    • Search Google Scholar
    • Export Citation
  • 93.

    O'Malley DP, Whalen M, Banks PM. Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome. Am J Hematol 2003;73:294295.

    • Search Google Scholar
    • Export Citation
  • 94.

    Veerappan R, Morrison M, Williams S, Variakojis D. Splenic rupture in a patient with plasma cell myeloma following G-CSF/GM-CSF administration for stem cell transplantation and review of the literature. Bone Marrow Transplant 2007;40:361364.

    • Search Google Scholar
    • Export Citation
  • 95.

    Watring NJ, Wagner TW, Stark JJ. Spontaneous splenic rupture secondary to pegfilgrastim to prevent neutropenia in a patient with non-small-cell lung carcinoma. Am J Emerg Med 2007;25:247248.

    • Search Google Scholar
    • Export Citation
  • 96.

    D'Souza A, Jaiyesimi I, Trainor L, Venuturumili P. Granulocyte colony-stimulating factor administration: adverse events. Transfus Med Rev 2008;22:280290.

    • Search Google Scholar
    • Export Citation
  • 97.

    Adler BK, Salzman DE, Carabasi MH. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001;97:33133314.

    • Search Google Scholar
    • Export Citation
  • 98.

    Grigg AP. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood 2001;97:39983999.

    • Search Google Scholar
    • Export Citation
  • 99.

    Kang EM, Areman EM, David-Ocampo V. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002;99:850855.

    • Search Google Scholar
    • Export Citation
  • 100.

    Gertz MA, Lacy MQ, Bjornsson J, Litzow MR. Fatal pulmonary toxicity related to the administration of granulocyte colony-stimulating factor in amyloidosis: a report and review of growth factor-induced pulmonary toxicity. J Hematother Stem Cell Res 2000;9:635643.

    • Search Google Scholar
    • Export Citation
  • 101.

    Bashir Q, Langford LA, Parmar S. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. J Clin Oncol 2011;29:e7980.

    • Search Google Scholar
    • Export Citation
  • 102.

    Martin WG, Ristow KM, Habermann TM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:76147620.

    • Search Google Scholar
    • Export Citation
  • 103.

    Azoulay E, Attalah H, Harf A. Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 2001;120:16951701.

    • Search Google Scholar
    • Export Citation
  • 104.

    Evens AM, Cilley J, Ortiz T. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol 2007;137:545552.

    • Search Google Scholar
    • Export Citation
  • 105.

    Boleti E, Mead GM. ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007;18:376380.

    • Search Google Scholar
    • Export Citation
  • 106.

    Herrmann F, Schulz G, Lindemann A. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study. Behring Inst Mitt 1988:107118.

    • Search Google Scholar
    • Export Citation
  • 107.

    Stern AC, Jones TC. The side-effect profile of GM-CSF. Infection 1992;20(Suppl 2):S124127.

  • 108.

    Food and Drug Administration. Sargramostim label information. Accessed July 28, 2016.

  • 109.

    Amato RJ, Hernandez-McClain J, Henary H. Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate. Urol Oncol 2009;27:813.

    • Search Google Scholar
    • Export Citation
  • 110.

    Winer ES, Miller KB, Chan GW. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. Oncology (Williston Park) 2005;19:1114.

    • Search Google Scholar
    • Export Citation
  • 111.

    Arning M, Kliche KO, Schneider W. GM-CSF therapy and capillary-leak syndrome. Ann Hematol 1991;62:8383.

  • 112.

    Al-Homaidhi A, Prince HM, Al-Zahrani H. Granulocyte-macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: two case reports and a review of the literature. Bone Marrow Transplant 1998;21:209214.

    • Search Google Scholar
    • Export Citation
  • 113.

    Emminger W, Emminger-Schmidmeier W, Peters C. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state. Blut 1990;61:219221.

    • Search Google Scholar
    • Export Citation
  • 114.

    Deeren DH, Zachee P, Malbrain ML. Granulocyte colony-stimulating factor-induced capillary leak syndrome confirmed by extravascular lung water measurements. Ann Hematol 2005;84:8994.

    • Search Google Scholar
    • Export Citation
  • 115.

    Vial T, Descotes J. Clinical toxicity of cytokines used as haemopoietic growth factors. Drug Saf 1995;13:371406.

  • 116.

    Relling MV, Boyett JM, Blanco JG. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003;101:38623867.

    • Search Google Scholar
    • Export Citation
  • 117.

    Smith RE, Bryant J, DeCillis A. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 2003;21:11951204.

    • Search Google Scholar
    • Export Citation
  • 118.

    Hershman D, Neugut AI, Jacobson JS. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007;99:196205.

    • Search Google Scholar
    • Export Citation
  • 119.

    Cosler LE, Eldar-Lissai A, Culakova E. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. Pharmacoeconomics 2007;25:343351.

    • Search Google Scholar
    • Export Citation
  • 120.

    Doorduijn JK, Buijt I, van der Holt B. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2004;89:11091117.

    • Search Google Scholar
    • Export Citation
  • 121.

    Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008;11:172179.

    • Search Google Scholar
    • Export Citation
  • 122.

    Numnum TM, Kimball KJ, Rocconi RP. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis. Int J Gynecol Cancer 2007;17:10191024.

    • Search Google Scholar
    • Export Citation
  • 123.

    Timmer-Bonte JN, Adang EM, Termeer E. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290296.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 3625 2589 191
PDF Downloads 1058 784 182
EPUB Downloads 0 0 0